A cultured-chicken safety finding is not a market approval

The signal

In the Food sector, two dated FDA notices mark a regulatory stage a cultured-meat product must clear before sale in the United States. The FDA's update of 16 November 2022 records that the agency completed its first pre-market consultation for a human food made from cultured animal cells, evaluating UPSIDE Foods' chicken-cell product and stating it had "no further questions" about the firm's own safety conclusion. A second, dated 21 March 2023, records the same finding for a chicken-cell submission from GOOD Meat. Both are safety consultations on a specific production process, not a market authorisation and not a blanket clearance for a food category.

The evidence

What the November 2022 notice measures is narrow: FDA's evaluation covered the production process for growing the company's chicken cells, the cell line and cell bank, manufacturing controls, and the inputs used, concluding it had no further questions about the safety conclusion the firm itself reached. FDA calls this a "voluntary pre-market consultation," and the same notice states the firm still needed facility registration with FDA and, separately, inspection approval and a mark of inspection from the US Department of Agriculture's Food Safety and Inspection Service before any product could reach a US market. The March 2023 notice repeats the pattern for a second company, showing the consultation route is repeatable rather than a one-off arrangement.

Timeframe and confidence

Confidence is high for what these two documents establish: FDA completed two safety consultations, five months apart, on two companies' cultured chicken-cell processes, and named a further USDA-FSIS step as outstanding at the time of each notice. This piece does not extend the record past what these documents show; it does not cite a dated USDA-FSIS grant of inspection, because no such document was opened in preparing it. Treating the FDA consultations as the whole approval story would overstate what they are: a food-safety sign-off on a process, ahead of a separate agency's separate gate.

What would change the reading

A dated USDA-FSIS document recording a grant of inspection for either company, or a dated retail listing confirming a product reached shelves or menus, would extend this record from a safety-consultation signal to a market-entry one. Their absence here is a gap in this piece's sourcing, not a claim that no such step occurred.

• Which specific document, if any, marks the point a novel food is permitted to be sold, as opposed to found safe in principle?
• Does a completed consultation apply to one firm's process, or does it set a standard other firms can rely on without their own review?
• How many regulatory gates sit between a safety finding and a product on a shelf, and which one does a headline usually skip?

Read this way, the FDA's two consultations are a documented signal about process safety and about a pathway's repeatability across firms, not about market presence, which is a distinct fact a strategist would need to verify separately.

Source trail

1. FDA Completes First Pre-Market Consultation for Human Food Made Using Animal Cell Culture Technologywww.fda.gov · Source publication: 2022-11-16 · Retrieved 2026-09-16

   Records FDA's completion of its first pre-market consultation, for UPSIDE Foods' cultured chicken-cell process, and names the further USDA-FSIS steps still required before market entry.

2. FDA Completes Second Pre-Market Consultation for a Human Food Made from Cultured Animal Cellswww.fda.gov · Source publication: 2023-03-21 · Retrieved 2026-09-16

   Records FDA's completion of a second consultation, for GOOD Meat's cultured chicken-cell process, confirming the pathway applied to more than one firm.

Read across the evidence

• FAO's food price index peaked the month after a partial reading
• A plant-based meat leader's 10-K recorded its first annual decline
• The farm count fell while the average farm grew

Governance & change · All 100 historical records